Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by a loss of dopaminergic innervation in the basal ganglia leading to motor and non-motor symptoms. Although historically considered a motor disorder, there are many neuropsychiatric symptoms associated with the disease, and the majority of diagnoses will progress to Parkinsons's Disease Dementia (PDD).
To diagnose Parkinson's Disease, the patient must present first with features of parkinsonism. However, this only means the have parkinsonism, and not Parkinson's Disease itself (for example they could have other neurodegnerative disorders such as progressive supranuclear palsy [PSP] or multisystem atrophy [MSA]). In order for Parkinson's Disease to be confirmed, at the vey least there needs to be an improvement/resolution of symptoms when patients are put on a trial of Sinemet (carbidopa-levodopa). The latest diagnostic criteria is based on the 2015 Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease.[4]
Essential Criterion |
---|
Must have parkinsonism, which is defined as bradykinesia, in combination with at least 1 of rest tremor or rigidity. Examination of all cardinal manifestations should be carried out as described in the MDS–Unified Parkinson Disease Rating Scale |
Clinically established PD requires |
1. Absence of absolute exclusion criteria 2. At least two supportive criteria 3. No red flags |
Clinically probable PD requires |
1. Absence of absolute exclusion criteria 2. Presence of red flags counterbalanced by supportive criteria (i.e. - if one red flag is present there must also be at least one supportive criterion; if two red flags, at least two supportive criteria are needed. If there are more than two red flags, clinically probable PD cannot be diagnosed). |
Supportive Criteria |
---|
1. Clear and dramatic beneficial response to dopaminergic therapy. During initial treatment, patient returned to normal or near-normal level of function. 2. Presence of levodopa-induced dyskinesia 3. Resting tremor of a limb, documented on clinical examination (in past, or on current examination) 4. The presence of either olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy |
TRAP
can be used to remember the physical symptoms of Parkinson's
T
- TremorR
- RigidityA
- Akinesia (lack of, or slow movement)P
- Postural instabilityThe presence of any of these features rules out PD |
---|
1. Unequivocal cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar oculomotor abnormalities (e.g. - sustained gaze evoked nystagmus, macro square wave jerks, hypermetric saccades) 2. Downward vertical supranuclear gaze palsy, or selective slowing of downward vertical saccades 3. Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia, defined according to consensus criteria within the first 5 years of disease 4. Parkinsonian features restricted to the lower limbs for more than 3 years 5. Treatment with a dopamine receptor blocker (e.g. - antipsychotic) or a dopamine-depleting agent in a dose and time-course consistent with drug-induced parkinsonism 6. Absence of observable response to high-dose levodopa despite at least moderate severity of disease 7. Unequivocal cortical sensory loss (i.e. - graphesthesia, stereognosis with intact primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia 8. Normal functional neuroimaging of the presynaptic dopaminergic system 9. Documentation of an alternative condition known to produce parkinsonism and plausibly connected to the patient’s symptoms, or, the expert evaluating physician, based on the full diagnostic assessment feels that an alternative syndrome is more likely than PD |
Red flags rule out probable PD diagnosis only when they cannot be counterbalanced by supportive criteria. |
---|
1. Rapid progression of gait impairment requiring regular use of wheelchair within 5 years of onset 2. A complete absence of progression of motor symptoms or signs over 5 or more years unless stability is related to treatment 3. Early bulbar dysfunction: severe dysphonia or dysarthria (speech unintelligible most of the time) or severe dysphagia (requiring soft food, NG tube, or gastrostomy feeding) within first 5 years 4. Inspiratory respiratory dysfunction: either diurnal or nocturnal inspiratory stridor or frequent inspiratory sighs 5. Severe autonomic failure in the first 5 y of disease. 6. Recurrent (> 1 per year) falls because of impaired balance within 3 years of onset 7. Disproportionate anterocollis (dystonic) or contractures of hand or feet within the first 10 years 8. Absence of any of the common nonmotor features of disease despite 5 years of disease duration. These include sleep dysfunction (sleep-maintenance insomnia, excessive daytime somnolence, symptoms of REM sleep behavior disorder), autonomic dysfunction (constipation, daytime urinary urgency, symptomatic orthostasis), hyposmia, or psychiatric dysfunction (depression, anxiety, or hallucinations) 9. Otherwise-unexplained pyramidal tract signs, defined as pyramidal weakness or clear pathologic hyperreflexia (excluding mild reflex asymmetry and isolated extensor plantar response) 10. Bilateral symmetric parkinsonism. The patient or caregiver reports bilateral symptom onset with no side predominance, and no side predominance is observed on objective examination |
Though not present in early stages, the majority of patients with Parkinson's Disease will have cognitive impairment and subsequently develop dementia.
Name | Rater | Description | Download |
---|---|---|---|
Unified Parkinson's Disease Rating Scale (UPDRS) | Clinician | The UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's | Download |
Many neurodegenerative disorders are on the differential diagnosis. These disorders may first present with neuropsychiatric symptoms, and patients may see a psychiatrist before any other specialist. A differential diagnosis for Parkinson's includes:
BALSA
can be used to remember the common treatments used in Parkinson'sB
- BromocriptineA
- AmantadineL
- Levodopa (with carbidopa)S
- Selegiline (and COMT inhibitors)Strategy | Medication | Notes |
---|---|---|
Dopamine agonists | Dopamine agonists (bromocriptine, pramipexole, ropinirole) | - |
Increase dopamine availability | Amantadine | Increases dopamine release and decreases dopamine reuptake |
Increased L-dopa availability | Levodopa, entacapone, tolcapone | These agents prevent peripheral (pre-BBB) L-Dopa degradation and increases central L-Dopa available for conversion to dopamine. Entacapone and tolcapone prevent peripheral L-Dopa degradation by inhibiting COMT. Used in conjunction with levodopa. |
Prevent dopamine breakdown | Selegiline, rasagiline | Block conversions of dopamine into DOPAC by selectively inhibiting MAO-B. |
Decrease excess cholinergic activity | Benztropine, trihexyphenidyl | Improves tremor and rigidity but has little effect on bradykinesia. |